Dual action of epigallocatechin-3-gallate in virus-induced cell Injury
- PMID: 38012348
- PMCID: PMC10682343
- DOI: 10.1186/s43141-023-00624-4
Dual action of epigallocatechin-3-gallate in virus-induced cell Injury
Abstract
Background: Viral infections cause damage and long-term injury to infected human tissues, demanding therapy with antiviral and wound healing medications. Consequently, safe phytochemical molecules that may control viral infections with an ability to provide wound healing to viral-induced tissue injuries, either topically or systemically, are advantageous. Herein, we hypothesized that epigallocatechin-3-gallate (EGCG), the most abundant polyphenol in green tea, might be effective as a wound healing, antiviral, and antifibrotic therapy.
Results: The antiviral activities of EGCG against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Herpes simplex virus type 2 (HSV-2) as well as its wound healing activities against different monolayer tissue (continuous and primary) systems were investigated. Consider its possible wound-healing advantages as well. To determine the safe concentrations of EGCG in green monkey kidney (Vero) and Vero-E6 cell lines, MTT assay was performed and showed high CC50 values of 405.1 and 322.9 μM, respectively. The antiviral activities of EGCG against SARS-CoV-2 and HSV-2, measured as half-maximal concentration 50 (IC50) concentrations, were 36.28 and 59.88 μM, respectively. These results confirm that the EGCG has remarkable viral inhibitory activities and could successfully suppress the replication of SARS-CoV-2 and HSV-2 in vitro with acceptable selectivity indices (SI) of 11.16 and 5.39, respectively. In parallel, the EGCG exhibits significant and dose/time-dependent anti-migration effects in human breast cancer cells (MCF-7), its resistant variation (MCF-7adr), and human skin fibroblast (HSF) indicating their potential to heal injuries in different internal and topical mammalian systems.
Conclusions: The EGCG has proven to be an efficient antiviral against SARS-CoV-2 and HSV-2, as well as a wound-healing phytochemical. We assume that EGCG may be a promising option for slowing the course of acute cellular damage induced by systemic (Coronavirus Disease 2019 (COVID-19)) or topical (HSV-2) viral infections.
Keywords: Antiviral activity; COVID-19; Cellular injury; EGCG; Green tea extract; Herpes simplex virus; Wound healing.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the review.
Figures
Similar articles
-
Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases.Phytomed Plus. 2023 Feb;3(1):100402. doi: 10.1016/j.phyplu.2022.100402. Epub 2022 Dec 30. Phytomed Plus. 2023. PMID: 36597465 Free PMC article. Review.
-
The potential of BEN815 as an anti-inflammatory, antiviral and antioxidant agent for the treatment of COVID-19.Phytomed Plus. 2021 Nov;1(4):100058. doi: 10.1016/j.phyplu.2021.100058. Epub 2021 Mar 18. Phytomed Plus. 2021. PMID: 35403084 Free PMC article.
-
Epigallocatechin-3-Gallate (EGCG) Inhibits SARS-CoV-2 Infection in Primate Epithelial Cells: (A Short Communication).Microbiol Infect Dis. 2021;5(2):10.33425/2639-9458.1116. doi: 10.33425/2639-9458.1116. Microbiol Infect Dis. 2021. PMID: 35291211 Free PMC article.
-
Potential protective mechanisms of green tea polyphenol EGCG against COVID-19.Trends Food Sci Technol. 2021 Aug;114:11-24. doi: 10.1016/j.tifs.2021.05.023. Epub 2021 May 25. Trends Food Sci Technol. 2021. PMID: 34054222 Free PMC article. Review.
-
Inhibition of herpes simplex virus type 1 with the modified green tea polyphenol palmitoyl-epigallocatechin gallate.Food Chem Toxicol. 2013 Feb;52:207-15. doi: 10.1016/j.fct.2012.11.006. Epub 2012 Nov 23. Food Chem Toxicol. 2013. PMID: 23182741 Free PMC article.
References
-
- Al-Karmalawy AA, Soltane R, Abo Elmaaty A, Tantawy MA, Antar SA, Yahya G, Chrouda A, Pashameah RA, Mustafa M, Abu Mraheil M, Mostafa A. Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. Vaccines (Basel). 2021;9(11):1317. doi: 10.3390/vaccines9111317. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous